Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
Chao Jing, Junyun Wang, Mingyue Zhu, Zhigang Bai, Zhao Baoyi, Jun Zhang, Jie Yin, Xiaobao Yang, Zongzhi Liu, Zhongtao Zhang, Wei Deng
Topics & Concepts
ApatinibMedicineInternal medicineGastroesophageal JunctionAdenocarcinomaOncologyGastric adenocarcinomaPhases of clinical researchGastroenterologyStomachProspective cohort studySurgeryCancerChemotherapyGastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentGastrointestinal Tumor Research and Treatment